As cell death was considerably higher following bumetanide administration, the drug may not be suitable as a potential therapy in AD or diseases involving altered KCC2 or NKCC1 expression, as regions with normal KCC2 and NKCC1 expression may be affected. The gene discussed is SLC12A5; the disease is Alzheimer disease.